Clinical Trial

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

Study acronym: rechARge
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.
Protocol Amendment History 1 change
notable Trial sites expanded: 279 -> 282 locations 2026-05-07
Trial Details
NCT Number NCT06764485
Lead Sponsor Celgene
Conditions Metastatic Castration-resistant Prostate Cancer
Enrollment 960 participants
Start Date 2025-03-13
Primary Completion 2027-09-12 (estimated)
Study Completion 2029-01-19 (estimated)
Updated on ClinicalTrials.gov 2026-07-22